SCHEMBL6424023

SCHEMBL6424023

Cn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccc([N+](=O)[O-])cc21

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 7/20 0.71
CCND1 P24385 7/20 0.71
PRKACA P17612 7/20 0.71
PRKACG P22612 7/20 0.71
PRKACB P22694 7/20 0.71
CCNE2 O96020 5/20 0.71
CCNE1 P24864 5/20 0.71
CDK2 P24941 5/20 0.71
CAMK2D Q13557 4/20 0.59
PIM1 P11309 2/20 0.53
CCNT1 O60563 1/20 0.53
CDK9 P50750 1/20 0.53
PRKCG P05129 2/20 0.53
PRKCB P05771 2/20 0.53
PRKCA P17252 2/20 0.53
PRKCH P24723 2/20 0.53
PRKCE Q02156 2/20 0.53
PRKCZ Q05513 2/20 0.53
PRKCD Q05655 2/20 0.53
PRKD3 O94806 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7058746 0.92 CCNE2 (0.71) CDK4CCND1PRKACAPRKACGPRKACB
Enmd-981693 SCHEMBL29350364 0.88 CCNE2 (0.69) CDK4CCND1CCNE2CCNE1CDK2
Enmd-981693 SCHEMBL608128 0.88 CCNE2 (0.69) CDK4CCND1CCNE2CCNE1CDK2
SCHEMBL7496386 0.88 CDK4 (0.55) CDK4CCND1PRKACAPRKACGPRKACB
SCHEMBL668748 0.87 CCNE2 (0.57) CDK4CCND1CCNE2CCNE1CDK2
SCHEMBL9087452 0.86 PRKACA (0.66) CDK4CCND1PRKACAPRKACGPRKACB
SCHEMBL9088178 0.85 PRKACA (0.67) CDK4CCND1PRKACAPRKACGPRKACB
SCHEMBL9087198 0.85 CDK4 (0.67) CDK4CCND1PRKACAPRKACGPRKACB
SCHEMBL7599053 0.84 CCNE2 (0.51) CDK4CCND1PRKACAPRKACGPRKACB
SCHEMBL9088204 0.84 CAMK2D (0.74) CDK4CCND1PRKACAPRKACGPRKACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0988863-B2 Stable complexes of poorly soluble compounds HOFFMANN LA ROCHE (CH) 2009-03-18 EP disclosed
EP-1242408-B1 SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION HOFFMANN LA ROCHE (CH) 2005-10-12 EP disclosed
EP-1441772-A2 POLYMER CONJUGATES OF PROTEIN KINASE C INHIBITORS Nektar Therapeutics Al, Corporation (US) 2004-08-04 EP disclosed
US-20030143185-A1 Polymer conjugates of protein kinase C inhibitors SHEARWATER CORPORATION 2003-07-31 US disclosed
EP-1064279-B1 SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION HOFFMANN LA ROCHE (CH) 2003-06-25 EP disclosed
WO-2003043632-A2 USE OF BISINDOLMALEIMIDE AND GEMCITABINE FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2003-05-30 WO disclosed
WO-2003037384-A2 POLYMER CONJUGATES OF PROTEIN KINASE C INHIBITORS NEKTAR THERAPEUTICS AL, CORPORATION (US) 2003-05-08 WO disclosed
EP-1242408-A1 SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION F. HOFFMANN-LA ROCHE AG (CH) 2002-09-25 EP disclosed
US-6313143-B1 USEFUL IN THERAPY OF CELL PROLIFERATIVE DISORDERS SUCH AS CANCER HOFFMANN-LA ROCHE INC. 2001-11-06 US disclosed
WO-2001044234-A1 SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION F. HOFFMANN-LA ROCHE AG (CH) 2001-06-21 WO disclosed
EP-1064279-A1 SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION F.HOFFMANN-LA ROCHE AG (CH) 2001-01-03 EP disclosed
WO-1999047518-A1 SUBSTITUTED BISINDOLYMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION F. HOFFMANN-LA ROCHE AG (CH) 1999-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030143185-A1 Polymer conjugates of protein kinase C inhibitors PRKCH, PRKCI, PRKCA CDK4 387/4885CCND1 2154/4885PRKACA 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.